Merge Healthcare /quotes/comstock/15*!mrge/quotes/nls/mrge (MRGE 2.20, +0.10, +4.76%) , a leading Health IT solutions provider, announced today that it was selected by Cato Research Ltd. to provide the proprietary etrials EDC solution through Merge's technology transfer program. This new agreement expands Merge's partnership with CATO to provide additional technology for clinical trials management, as well as extending the relationship for an additional five years.

"We have enjoyed a long-standing partnership with Merge Healthcare for their clinical trial solutions," noted Allen Cato, M.D., Ph.D., and CEO of Cato Research Ltd. "The etrials(R) technology has been consistent and intuitive, and the Merge team has been quick to help us use it successfully. Adding the etrials EDC platform in a technology transfer model will enable our company to efficiently build and deliver solutions to help our customers run cost-effective clinical studies."

The technology transfer program allows CATO to use the etrials EDC system to build and deploy custom clinical trial studies that leverage the powerful reporting capabilities of Merge's technology. Because the etrials EDC solution is built on a SaaS platform, it can be licensed on a subscription or study basis. In addition, Merge's etrials IVR(TM) and ePRO(TM) solutions can be integrated with the EDC system to provide comprehensive eClinical solutions. Merge's team of clinical trial experts will also provide training and support to CATO.

Read More....